<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556178</url>
  </required_header>
  <id_info>
    <org_study_id>2011-14612</org_study_id>
    <nct_id>NCT01556178</nct_id>
  </id_info>
  <brief_title>Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research</brief_title>
  <official_title>Collection of Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In normal patients, blood and cerebrospinal fluid (CSF) contain circulating cells and other
      molecules such as proteins and nucleic acids. In patients with central nervous system (CNS)
      and other conditions, the levels of these molecules may be altered. In several other studies
      at our institution, the investigators are investigating such molecules in tumor specimens as
      well as the blood and cerebrospinal fluid of pediatric patients with CNS tumors. However,
      these levels are difficult to interpret without comparing them to levels in patients without
      CNS tumors. The investigators propose a study to collect small amounts of blood and
      cerebrospinal fluid from pediatric patients without CNS tumors who are undergoing a
      diagnostic or therapeutic neurosurgical procedure aimed at addressing altered CSF dynamics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>levels of miRNAs in the blood and CSF</measure>
    <time_frame>2 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survivin and biologic markers levels in the CSF and blood</measure>
    <time_frame>2 yrs</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Hydrocephalus</condition>
  <arm_group>
    <arm_group_label>Children without central nervous system tumors</arm_group_label>
    <description>Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and cerebrospinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All children without central nervous system tumors between the ages of 1 year and 21 years
        who are undergoing a neurosurgical procedure to address hydrocephalus during which CSF will
        be obtained will be considered
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children without central nervous system tumors who are undergoing a neurosurgical
             procedure to address hydrocephalus during which CSF will be obtained

          -  Between the ages of 1 year and 21 years

          -  Patients must be having blood draws, lumbar punctures or CSF sampling from Ommaya
             reservoirs or VPS as part of routine clinical care.

        Exclusion Criteria:

          -  Patients who do not require routine blood draws and/or CSF collection as part of their
             routine clinical care

          -  Patients who are considered too ill to participate as determined by their treating
             physician

          -  Patients with documented bacterial of viral infections of the CSF, brain parenchyma
             and/or neurosurgical devices and/or

          -  Patients with suspected de-myelinating conditions

          -  Patients who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rishi Lulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fernandez-L A, Northcott PA, Taylor MD, Kenney AM. Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle. 2009 Dec 15;8(24):4049-54. Epub 2009 Dec 5.</citation>
    <PMID>19901543</PMID>
  </reference>
  <reference>
    <citation>Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.</citation>
    <PMID>18663219</PMID>
  </reference>
  <reference>
    <citation>Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008 Jul;110(1):13-21. doi: 10.1016/j.ygyno.2008.04.033. Erratum in: Gynecol Oncol. 2010 Jan;116(1):153.</citation>
    <PMID>18589210</PMID>
  </reference>
  <reference>
    <citation>Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008 May;141(5):672-5. doi: 10.1111/j.1365-2141.2008.07077.x. Epub 2008 Mar 3.</citation>
    <PMID>18318758</PMID>
  </reference>
  <reference>
    <citation>Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010 Jul 1;127(1):118-26. doi: 10.1002/ijc.25007.</citation>
    <PMID>19876917</PMID>
  </reference>
  <reference>
    <citation>Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009 Oct;58(10):1375-81. doi: 10.1136/gut.2008.167817. Epub 2009 Feb 6.</citation>
    <PMID>19201770</PMID>
  </reference>
  <reference>
    <citation>Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol. 2009;2009:950201. doi: 10.1155/2010/950201. Epub 2009 Jul 20.</citation>
    <PMID>19639033</PMID>
  </reference>
  <reference>
    <citation>Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009 May 19;2:89. doi: 10.1186/1756-0500-2-89.</citation>
    <PMID>19454029</PMID>
  </reference>
  <reference>
    <citation>Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002 Feb 15;20(4):1063-8.</citation>
    <PMID>11844831</PMID>
  </reference>
  <reference>
    <citation>Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boué DR, Hayes J, Altura RA. Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer. 2005 Jan 31;92(2):359-65.</citation>
    <PMID>15655550</PMID>
  </reference>
  <reference>
    <citation>Ikeguchi M, Kaibara N. survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer. 2002 Oct 7;87(8):883-7.</citation>
    <PMID>12373603</PMID>
  </reference>
  <reference>
    <citation>Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol. 2002 Mar;11(1):33-40.</citation>
    <PMID>11854600</PMID>
  </reference>
  <reference>
    <citation>Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999 Jul;17(7):2100-4.</citation>
    <PMID>10561264</PMID>
  </reference>
  <reference>
    <citation>Mori A, Wada H, Nishimura Y, Okamoto T, Takemoto Y, Kakishita E. Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol. 2002 Feb;75(2):161-5.</citation>
    <PMID>11939262</PMID>
  </reference>
  <reference>
    <citation>Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002 Mar 18;86(6):886-92.</citation>
    <PMID>11953819</PMID>
  </reference>
  <reference>
    <citation>Takamizawa S, Scott D, Wen J, Grundy P, Bishop W, Kimura K, Sandler A. The survivin:fas ratio in pediatric renal tumors. J Pediatr Surg. 2001 Jan;36(1):37-42.</citation>
    <PMID>11150435</PMID>
  </reference>
  <reference>
    <citation>Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998 Mar 21;351(9106):882-3.</citation>
    <PMID>9525374</PMID>
  </reference>
  <reference>
    <citation>Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000 Feb 3;19(5):617-23.</citation>
    <PMID>10698506</PMID>
  </reference>
  <reference>
    <citation>Ito R, Asami S, Motohashi S, Ootsuka S, Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H, Suzuki T. Significance of survivin mRNA expression in prognosis of neuroblastoma. Biol Pharm Bull. 2005 Apr;28(4):565-8.</citation>
    <PMID>15802787</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Rishi Lulla</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hydrocephalus</keyword>
  <keyword>Survivin</keyword>
  <keyword>miRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Hydrocephalus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

